{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:44:16Z","timestamp":1789094656744,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11739-025-03967-7","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:48:36Z","timestamp":1748677716000},"page":"645-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic associated steatotic liver disease in renal transplant recipients: a retrospective cohort study"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2742-237X","authenticated-orcid":false,"given":"Carmine","family":"Secondulfo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8245-5305","authenticated-orcid":false,"given":"Pietro","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Iacuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Angela","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-9136","authenticated-orcid":false,"given":"Luca","family":"Apicella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Vecchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0550-8201","authenticated-orcid":false,"given":"Mario","family":"Masarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1399-6498","authenticated-orcid":false,"given":"Marcello","family":"Persico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0845-1194","authenticated-orcid":false,"given":"Giancarlo","family":"Bilancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"3967_CR1","doi-asserted-by":"publisher","unstructured":"(2013) Summary of Recommendation Statements. Kidney International Supplements 3:5\u201314. https:\/\/doi.org\/10.1038\/kisup.2012.77","DOI":"10.1038\/kisup.2012.77"},{"key":"3967_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov B, Purcell CA, Levey AS et al (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 395:709\u2013733. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3","journal-title":"The Lancet"},{"key":"3967_CR3","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","volume":"65","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Sookoian S (2024) From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res 65:100485. https:\/\/doi.org\/10.1016\/j.jlr.2023.100485","journal-title":"J Lipid Res"},{"key":"3967_CR4","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu V, Boursier J, AFEF Group for the Study of Liver Fibrosis (2024) (2024) Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol 80:e51\u2013e52. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.017","journal-title":"J Hepatol"},{"key":"3967_CR5","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC-T, Wong GL-H et al (2024) Can we use old NAFLD data under the new MASLD definition? J Hepatol 80:e54\u2013e56. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021","journal-title":"J Hepatol"},{"key":"3967_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"3967_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S2213-8587(19)30026-9","volume":"7","author":"LM Jaacks","year":"2019","unstructured":"Jaacks LM, Vandevijvere S, Pan A et al (2019) The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol 7:231\u2013240. https:\/\/doi.org\/10.1016\/S2213-8587(19)30026-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3967_CR8","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P et al (2019) Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9th edition. Diabetes Res Clin Pract 157:107843. https:\/\/doi.org\/10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"key":"3967_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E et al (2021) Global epidemiology of dyslipidaemias. Nat Rev Cardiol 18:689\u2013700. https:\/\/doi.org\/10.1038\/s41569-021-00541-4","journal-title":"Nat Rev Cardiol"},{"key":"3967_CR10","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","volume":"50","author":"J Bilson","year":"2024","unstructured":"Bilson J, Mantovani A, Byrne CD, Targher G (2024) Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab 50:101506. https:\/\/doi.org\/10.1016\/j.diabet.2023.101506","journal-title":"Diabetes Metab"},{"key":"3967_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","volume":"21","author":"G Musso","year":"2015","unstructured":"Musso G, Cassader M, Cohney S et al (2015) Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med 21:645\u2013662. https:\/\/doi.org\/10.1016\/j.molmed.2015.08.005","journal-title":"Trends Mol Med"},{"key":"3967_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/ijms17040562","volume":"17","author":"M Marcuccilli","year":"2016","unstructured":"Marcuccilli M, Chonchol M (2016) NAFLD and chronic kidney disease. Int J Mol Sci 17:562. https:\/\/doi.org\/10.3390\/ijms17040562","journal-title":"Int J Mol Sci"},{"key":"3967_CR13","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","volume":"18","author":"K Matsushita","year":"2022","unstructured":"Matsushita K, Ballew SH, Wang AY-M et al (2022) Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol 18:696\u2013707. https:\/\/doi.org\/10.1038\/s41581-022-00616-6","journal-title":"Nat Rev Nephrol"},{"key":"3967_CR14","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.transproceed.2017.09.005","volume":"49","author":"G Bilancio","year":"2017","unstructured":"Bilancio G, Celano M, Cozza V et al (2017) Early prediction of cardiovascular disease in kidney transplant recipients. Transpl Proc 49:2092\u20132098. https:\/\/doi.org\/10.1016\/j.transproceed.2017.09.005","journal-title":"Transpl Proc"},{"key":"3967_CR15","doi-asserted-by":"publisher","first-page":"100822","DOI":"10.1016\/j.ijcha.2021.100822","volume":"35","author":"M Coyle","year":"2021","unstructured":"Coyle M, Flaherty G, Jennings C (2021) A critical review of chronic kidney disease as a risk factor for coronary artery disease. Int J Cardiol Heart Vasc 35:100822. https:\/\/doi.org\/10.1016\/j.ijcha.2021.100822","journal-title":"Int J Cardiol Heart Vasc"},{"key":"3967_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/j.ajkd.2006.06.005","volume":"48","author":"MA Roberts","year":"2006","unstructured":"Roberts MA, Hare DL, Ratnaike S, Ierino FL (2006) Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 48:341\u2013360. https:\/\/doi.org\/10.1053\/j.ajkd.2006.06.005","journal-title":"Am J Kidney Dis"},{"key":"3967_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D et al (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143:1157\u20131172. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050686","journal-title":"Circulation"},{"key":"3967_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/ki.2009.377","volume":"77","author":"BL Kasiske","year":"2010","unstructured":"Kasiske BL, Zeier MG, Chapman JR et al (2010) KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 77:299\u2013311. https:\/\/doi.org\/10.1038\/ki.2009.377","journal-title":"Kidney Int"},{"key":"3967_CR19","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee (2023) 2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142024. Diabetes Care 47:S20\u2013S42. https:\/\/doi.org\/10.2337\/dc24-S002","journal-title":"Diabetes Care"},{"key":"3967_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1242\/dmm.001180","volume":"2","author":"PL Huang","year":"2009","unstructured":"Huang PL (2009) A comprehensive definition for metabolic syndrome. Dis Model Mech 2:231. https:\/\/doi.org\/10.1242\/dmm.001180","journal-title":"Dis Model Mech"},{"key":"3967_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2009.05.023","volume":"51","author":"NF Schwenzer","year":"2009","unstructured":"Schwenzer NF, Springer F, Schraml C et al (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51:433\u2013445. https:\/\/doi.org\/10.1016\/j.jhep.2009.05.023","journal-title":"J Hepatol"},{"key":"3967_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V et al (2024) EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"3967_CR23","doi-asserted-by":"publisher","DOI":"10.1159\/000543276","author":"A Fari\u00f1a-Hern\u00e1ndez","year":"2024","unstructured":"Fari\u00f1a-Hern\u00e1ndez A, Gonz\u00e1lez-Rinne A, Hern\u00e1ndez-Bustabad A et al (2024) Metabolic syndrome, nonalcoholic fatty liver disease, and graft inflammation: an unaddressed pathogenic link after kidney transplantation. Nephron. https:\/\/doi.org\/10.1159\/000543276","journal-title":"Nephron"},{"key":"3967_CR24","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.3390\/nu16193344","volume":"16","author":"I-H Lin","year":"2024","unstructured":"Lin I-H, Yu Y-P, Duong TV et al (2024) Effect of obesity and metabolic health status on metabolic-associated steatotic liver disease among renal transplant recipients using hepatic steatosis index. Nutrients 16:3344. https:\/\/doi.org\/10.3390\/nu16193344","journal-title":"Nutrients"},{"key":"3967_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73:202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"},{"key":"3967_CR26","doi-asserted-by":"publisher","first-page":"788881","DOI":"10.3389\/fmed.2021.788881","volume":"8","author":"L Marc","year":"2021","unstructured":"Marc L, Mihaescu A, Lupusoru R et al (2021) Liver steatosis: better predictor of CKD in MAFLD than liver fibrosis as determined by transient elastography with controlled attenuation parameter. Front Med (Lausanne) 8:788881. https:\/\/doi.org\/10.3389\/fmed.2021.788881","journal-title":"Front Med (Lausanne)"},{"key":"3967_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ecl.2016.06.005","volume":"45","author":"F Bril","year":"2016","unstructured":"Bril F, Cusi K (2016) Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus. Endocrinol Metab Clin North Am 45:765\u2013781. https:\/\/doi.org\/10.1016\/j.ecl.2016.06.005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3967_CR28","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/ndt\/gfx381","volume":"34","author":"R Chinnadurai","year":"2019","unstructured":"Chinnadurai R, Ritchie J, Green D, Kalra PA (2019) Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrol Dial Transplant 34:449\u2013457. https:\/\/doi.org\/10.1093\/ndt\/gfx381","journal-title":"Nephrol Dial Transplant"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-03967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-025-03967-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-03967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:01:15Z","timestamp":1775642475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-025-03967-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3967"],"URL":"https:\/\/doi.org\/10.1007\/s11739-025-03967-7","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is part of the \u201cSalerno CKD Cohort Study\u201d, an ongoing, open-ended, observational study. It was reviewed and approved by the local institutional ethical committee (2012\u2014n. 589), and was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki), included a written informed consent, was registered in the public registry of the Italian Drug Agency (Agenzia Italiana del FArmaco, AIFA, ID n. 654) and in the public registry of the Authority for Privacy of the Italian Parliament (Garante della Privacy, n. 102400183803).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}